You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Introducing Anoro Ellipta

Anoro Ellipta (55 micrograms/22 micrograms inhalation powder) is a long acting muscarinic agonist/long acting Beta2-adrenergic agonists (LAMA/LABA) and is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).1

Request a placebo

Only Anoro Ellipta

Demonstrated 1.4x statistically superior lung function improvement vs. TIO/OLO (180mL vs. 128mL change from baseline in trough FEV1 at week 8; 95% CI 28, 77; p<0.001)****2

Discover more >

Prescribe Anoro
Ellipta­­­1

To give your COPD patients 2x the odds of achieving a clinically meaningful improvement in lung function vs. tiotropium olodaterol2

Read more >

Anoro Ellipta Head-to-Head Study

Watch lead author Dr. Gregory Feldman provide an overview of the Anoro Ellipta Head-to-Head Study by clicking the video above

 

Knowledge Base

Watch webinars and videos, featuring experts in the respiratory field.

Find out more

 

References:

  1. Anoro Ellipta 52/22 mcg SPC.
  2. Feldman G.J et al. Adv Ther 2017; 34:doi 10.1007/s12325-017-0626-4.

 

Innoviva logo

© 2018 GlaxoSmithKline Group of Companies. Anoro and Ellipta are trademarks of the GlaxoSmithKline group of companies.
Anoro Ellipta was developed in collaboration with Innoviva.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.